Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $917000.0.

  • Insight Molecular Diagnostics' Treasury Shares changed N/A to $917000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $917000.0, marking a year-over-year change of. This contributed to the annual value of $100000.0 for FY2024, which is 190000.0% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Treasury Shares is $917000.0.
  • Insight Molecular Diagnostics' 5-year Treasury Shares high stood at $1.5 million for Q3 2022, and its period low was $5000.0 during Q3 2023.
  • For the 5-year period, Insight Molecular Diagnostics' Treasury Shares averaged around $359294.1, with its median value being $161000.0 (2021).
  • As far as peak fluctuations go, Insight Molecular Diagnostics' Treasury Shares plummeted by 9965.66% in 2023, and later soared by 1502000.0% in 2025.
  • Insight Molecular Diagnostics' Treasury Shares (Quarter) stood at $121000.0 in 2021, then crashed by 81.82% to $22000.0 in 2022, then tumbled by 77.27% to $5000.0 in 2023, then surged by 1900.0% to $100000.0 in 2024, then soared by 817.0% to $917000.0 in 2025.
  • Its Treasury Shares was $917000.0 in Q3 2025, compared to $792000.0 in Q2 2025 and $756000.0 in Q1 2025.